

# Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T-cell lymphoma

Adrien Picod,<sup>1\*</sup> Suella Martino,<sup>1\*</sup> Pascale Cervera,<sup>2\*</sup> Gregory Manuceau,<sup>1</sup> Marc Arca,<sup>1</sup> Monica Wittner,<sup>1</sup> YanYan Zhang,<sup>1</sup> He Liang,<sup>1</sup> Florian Beghi,<sup>1</sup> Eric Solary,<sup>1</sup> Fawzia Louache<sup>1,3,4</sup> and Paul Coppo<sup>1,5</sup>

<sup>1</sup>Inserm U1287, Gustave Roussy Institute, Villejuif; <sup>2</sup>Service d'Anatomopathologie, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris; <sup>3</sup>Université Paris-Sud, Orsay; <sup>4</sup>French National Center for Scientific Research (CNRS) Research Group (GDR) 3697 MicroNiT and <sup>5</sup>Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), Service d'Hématologie, AP-HP - Sorbonne Université, Paris, France.

*\*AP, SM and PC contributed equally as co-first authors.*

Correspondence:

P. COPPO - paul.coppo@aphp.fr

<https://doi.org/10.3324/haematol.2021.280349>

## Supplemental material

**Supplemental Table 1.** Interferon- $\gamma$  production by NKTCL cell lines according to JAK3, MEK and AKT activity.

	Control		NKL		KHYG-1	
	IL-2-	IL-2+	IL-2-	IL-2+	IL-2-	IL-2+
<b>Vehicle</b>	0	45 (17)	6,1 (1.4)	149 (14)	23 (7)	213 (18)
<b>+ CP-690550</b>	0	0	0	13.3 (2.3)	0	4.6 (2.7)
<b>+ UO126</b>	0	0	0	4 (5.4)	0	72 (3)
<b>+ GDC-0941</b>	0	0	0	0	0	0

Interferon- $\gamma$  concentrations (expressed as mean (standard deviation) pg/mL/10<sup>6</sup> **viable** cells) were assessed by ELISA using Quantikine assay (R&D Systems, Abingdon, UK) according to the supplier's instructions, with the use of a Microplate Reader model 680 (Life Science, Bio-Rad, Marne la Coquette, France) and the Microplate Manager 5.2 software. Culture supernatants were collected 2 days following chemical inhibitors exposure targeting JAK3 (CP-690550, 50 nM), MEK1/MEK2 (UO126, 10  $\mu$ M) or PI3K/AKT (GDC-0941, 5  $\mu$ M). Results were obtained from at least three independent experiments. Interferon- $\gamma$  concentrations were normalized according to the number of viable cells at time of supernatant collection. IL-2: interleukin-2. Control was a NK cell population from a healthy donor. Vehicle was dimethylsulfoxyde.


**Supplemental Table 2.** Blood cell count in mice with JAK3 A573V-induced lymphoproliferative disease.

	<b>Empty vector (N=2)</b>	<b>JAK3 WT (N=2)</b>	<b>JAK3 A573V (N=2)</b>
<b>White blood cells (10<sup>9</sup>/L)</b>	11.90 (4.8)	7.45 (0.04)	4.36 (0.4)
<b>Monocytes (10<sup>9</sup>/L)</b>	0.18 (0.04)	0.34 (0.18)	0.25 (0.07)
<b>Lymphocytes (10<sup>9</sup>/L)</b>	6.6 (0.09)	10.5 (3.65)	3.3 (0.28)
<b>Neutrophils (10<sup>9</sup>/L)</b>	0.7 (0.02)	1.48 (0.85)	0.85 (0.21)
<b>Platelets (10<sup>9</sup>/L)</b>	596 (201)	300 (276)	99 (17)
<b>Hemoglobin (g/dL)</b>	11.6 (0.57)	11.2 (0.71)	10.0 (0.42)

Mice were sampled before sacrifice for autopsy. Results are expressed as mean (standard deviation). WT: wild type.



Supplemental Figure 1

A.




**Supplemental Figure 1**

**B.**




Supplemental Figure 1

C




D




**Supplemental Figure 1**

**E**



**F**



## Supplemental Figure S1

**Hyperresponsiveness of NKTCL cell lines to rIL-2 and interferon- $\gamma$  hypersecretion are JAK3-dependent.** (A) Proliferation of MEC04 cells in the presence or absence of rIL-2 100 U/L. MEC04 cells were cultured under rIL-2 100 U/L and in the presence of the JAK3 inhibitor CP-690550 50 nM. Normal NK cells obtained from healthy donors cultured with rIL-2 100 U/L, or in the presence of rIL-10 ng/mL (that does not activate JAK3) were used as **controls**<sup>1</sup>. The significance of differences between experimental conditions was determined by the use of Student t test. \*,  $P < 0.001$ ; \*\*,  $P < 0.0001$ . (B) Western blot analysis of the expression level of total and phosphorylated STAT3 as a substrate of JAK3. MEC04 cells were cultured overnight without rIL-2 and subsequently stimulated with rIL-2 50 U/L for 30 minutes. MEC04 cells were also exposed to CP-690550 100 nM for 15 minutes before rIL-2 stimulation. Normal NK cells cultured with or without rIL-2 100 U/L were used for comparison, and  $\beta$ -Actin as loading control. The relative intensity of the immunoreactive bands (mean $\pm$ SD of 3 independent experiments) was quantified by autoradiography (arbitrary units, AU), using the ImageJ Software. The statistical significance was calculated by the Student t test. \*,  $p \leq 0.05$ . (C) Western blot analysis of the expression levels of total and phosphorylated JAK3, STAT3, AKT and ERK1/2 in NKL cell line following a 48-h exposition to the JAK3 inhibitor CP-690550 50 nM.  $\beta$ -Actin was used as loading control. (D) Specific JAK3 inhibition decreases NKL cell line growth and interferon- $\gamma$  hypersecretion. NKL cells were transfected with *JAK3*-specific or scrambled control siRNAs (Scr), then cultured in the presence of rIL-2 for 2 days and analyzed by western blotting at day 2. After trypan blue coloration, the number of viable cells (i.e., not colored by trypan blue) was evaluated daily. (E) Western blot analysis of the expression levels of total and phosphorylated JAK3, STAT3, AKT and ERK1/2 in NKL cell line at day-2 following specific JAK3 inhibition.  $\beta$ -Actin was used as loading control. Abbreviations: Scr: scrambled; siJAK3: anti-*JAK3* siRNA. (F) Interferon- $\gamma$  hypersecretion involves JAK3



substrates MEK1/2 and AKT. NKL cells were cultured for 2 days in the presence of rIL-2 100 U/L and exposed to the MEK1/MEK2 (UO126, 10  $\mu$ M) or PI3K/AKT (GDC-0941, 5  $\mu$ M) inhibitors. At day-2, supernatant was collected for interferon- $\gamma$  concentration measurement for each condition. Day-2 western blot analysis of the expression levels of total and phosphorylated AKT and ERK1/2.  $\beta$ -Actin was used as loading control.

1. Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. *Immunology* 2007;122(4):486-95.